TreeFrog Therapeutics Receives €3M Non-Dilutive Funding

healthcareTreeFrog Therapeutics, a Bordeaux, France-based expert stem cell company, received close to €3M ($3.3M) in non-dilutive funding from French and European programs.

The company received:
– €450k ($478.8k) from French government’s Bpifrance as part of Phase 2 of the i-Nov Innovation Challenge, as well as
– €2.4M ($2.6M) from the European Commission as part of Phase 2 of the SME Instrument (now EIC Accelerator, part of the EU’s Horizon 2020 program).

This funding will be used to accelerate the cGMP certification and scale-up of C-Stem™, TreeFrog Therapeutics’ technology for the mass-production of cell therapies. Compatible with conventional bioreactors, C-Stem™ will turn into a regulatory body compliant bioproduction platform to service the cell therapy industry with stem cells and differentiated therapeutic cells.
The company aims to deliver its first clinical-grade batches by 2021, introducing a new quality standard for cellular products and reducing production costs by at least 10-fold.

Founded in November 2018 in Bordeaux, France and led by Maxime Feyeux, president, CSO, and Kevin Alessandri, CEO & CTO, TreeFrog Therapeutics is a stem cell company that, through strategic partnerships and co-developments with pharma companies and cell therapy initiatives, aims to hasten the clinical development of cell therapies and facilitate market access.
TreeFrog Therapeutics raised €7.1M ($7.8M) in 2019 with XAnge (Siparex Group), Galia Gestion and historical investors Irdi Soridec, Aquiti Gestion and SATT Aquitaine.



Join the discussion